Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
February 05 2024 - 5:24AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
SCHEDULE 13G/A
Under the Securities Exchange Act of 1934
(Amendment No. 3)*
Takeda
Pharmaceutical Company Limited |
(Name of Issuer) |
|
Common Stock |
(Title of Class of Securities) |
|
874060205 |
(CUSIP Number) |
|
December 31, 2023 |
(Date of Event which Requires Filing of this Statement) |
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
☒ Rule
13d-1(b)
☐ Rule
13d-1(c)
☐ Rule
13d-1(d)
_____________________________
* The remainder of this cover page shall be filled out for a reporting person’s
initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information
which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be
deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise
subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
CUSIP No. 874060205 |
13G/A |
|
1. |
NAMES OF REPORTING PERSONS
Sumitomo Mitsui Trust Holdings, Inc.
|
2. |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
(a) ☐ |
|
|
(b) ☐
|
3. |
SEC USE ONLY
|
4. |
CITIZENSHIP OR PLACE OF ORGANIZATION
Japan
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH |
5. |
SOLE VOTING POWER
0
|
6. |
SHARED VOTING POWER
79,074,334
|
7. |
SOLE DISPOSITIVE POWER
0
|
8. |
SHARED DISPOSITIVE POWER
87,400,834
|
9. |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
87,400,834
|
10. |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see
instructions)
☐ |
11. |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
5.5% |
12. |
TYPE OF REPORTING PERSON (see instructions)
HC, FI |
Item 1(a). Name of Issuer:
Takeda Pharmaceutical Company Limited
Item 1(b). Address of Issuer’s Principal
Executive Offices:
1-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8668,
Japan
Item 2(a). Name of Person Filing:
Sumitomo Mitsui Trust Holdings, Inc.
Item 2(b). Address of Principal Business Office
or, if None, Residence:
1-4-1 Marunouchi, Chiyoda-ku, Tokyo 100-8233, Japan
Item 2(c). Citizenship:
Japan
Item 2(d). Title of Class of Securities:
Common Stock
Item 2(e). CUSIP Number:
874060205
| Item 3. | If this Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a: |
(a) |
☐ |
Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o); |
|
|
|
(b) |
☐ |
Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c); |
|
|
|
(c) |
☐ |
Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c); |
|
|
|
(d) |
☐ |
Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); |
|
|
|
(e) |
☐ |
An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E); |
|
|
|
(f) |
☐ |
An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F); |
|
|
|
(g) |
☒ |
A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G); |
|
|
|
(h) |
☐ |
A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); |
|
|
|
(i) |
☐ |
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); |
|
|
|
(j) |
☒ |
A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J); |
|
|
|
(k) |
☐ |
Group, in accordance with §240.13d-1(b)(1)(ii)(K). |
If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J),
please specify the type of institution: Parent Holding Company
Provide the following information regarding the aggregate
number and percentage of the class of securities of issuer identified in Item 1.
(a) |
|
Amount beneficially owned: 87,400,834 |
|
|
|
(b) |
|
Percent of class: 5.5% |
|
|
|
(c) |
|
Number of shares as to which such person has: |
|
|
|
(i) |
|
Sole power to vote or to direct the vote: 0 |
|
|
|
(ii) |
|
Shared power to vote or to direct the vote: 79,074,334 |
|
|
|
(iii) |
|
Sole power to dispose or to direct the disposition of: 0 |
|
|
|
(iv) |
|
Shared power to dispose or to direct the disposition of: 87,400,834 |
| Item 5. | Ownership of Five Percent or Less of a Class. |
If this statement is being filed to report the fact that
as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities,
check the following. ☐
| Item 6. | Ownership of More than Five Percent on Behalf of Another Person. |
Not applicable.
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company. |
See Exhibit A.
| Item 8. | Identification and Classification of Members of the Group. |
Not applicable.
| Item 9. | Notice of Dissolution of Group. |
Not applicable.
By signing below I certify that, to the best of my knowledge
and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired
and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and
were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
SIGNATURE
After reasonable inquiry and to the best of my knowledge
and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: February 5, 2024
|
Sumitomo Mitsui Trust Holdings, Inc. |
|
(Company) |
|
|
|
/s/ Hideaki Takamiya |
|
(Signature)
Hideaki Takamiya / Senior Manager
of Risk
Management Dept |
|
(Name/Title) |
Exhibit A
Pursuant to the instructions in Item 7 of Schedule
13G, portions of the securities being reported on by Sumitomo Mitsui Trust Holdings, Inc. as a parent holding company are owned,
or may be deemed to be beneficially owned, by its subsidiaries: each of (a) Sumitomo Mitsui Trust Asset Management Co., Ltd. and
(b) Nikko Asset Management Co., Ltd. is classified as an investment adviser in accordance with §240.13d-1(b)(1)(ii)(E) and
as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J).
Page 6 of 6
Takeda Pharmaceutical (PK) (USOTC:TKPHF)
Historical Stock Chart
From Oct 2024 to Oct 2024
Takeda Pharmaceutical (PK) (USOTC:TKPHF)
Historical Stock Chart
From Oct 2023 to Oct 2024